The pandemic’s effects on biotech are just beginning
The novel coronavirus’s disruptive effect on biotech has turned 2020 into an unpredictable environment for scores of make-or-break clinical trials.
As STAT’s Adam Feuerstein reports, there are more than 120 Phase 3 studies slated to read out by the end of the year. But each day seems to bring news of drug companies pausing enrollment out of coronavirus caution. Yesterday, it was Eli Lilly. On Sunday, it was Galapagos. Today could bring another.
That creates a difficult situation for patients involved in studies, but also the many others waiting on new treatments. It also injects uncertainty into the whole biopharma industry at a time when investors are already skittish about plummeting indices and the risk of a prolonged financial downturn.
Read more.
As STAT’s Adam Feuerstein reports, there are more than 120 Phase 3 studies slated to read out by the end of the year. But each day seems to bring news of drug companies pausing enrollment out of coronavirus caution. Yesterday, it was Eli Lilly. On Sunday, it was Galapagos. Today could bring another.
That creates a difficult situation for patients involved in studies, but also the many others waiting on new treatments. It also injects uncertainty into the whole biopharma industry at a time when investors are already skittish about plummeting indices and the risk of a prolonged financial downturn.
Read more.
.png)
No hay comentarios:
Publicar un comentario